Clinical Trials Page  
line decor
  L-MARC Home Page  ::  
line decor
   
 
Miscellaneous Clinical Trials

 

A MULTICENTER, RANDOMIZED, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA.
(PRINCIPAL INVESTIGATOR, 2016)

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE (PRINCIPAL (PRINCIPAL INVESTIGATOR, 2016)

DR. REDDY LABORATORIES, LTD. : A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, TOLERABILITY, AND SAFETY STUDY OF DFN-15 IN EPISODIC MIGRAINE WITH OR WITHOUT AURA
(PRINCIPLE INVESTIGATOR, 2016)

CLINICAL EVALUATION OF THE ACCURACY OF THE AFINION LIPID PANEL TEST IN A POINT OF CARE SETTING.
(PRINCIPAL INVESTIGATOR, 2016)

CLINICAL EVALUATION OF THE WHOLE BLOOD AND SERUM PRECISION OF THE AFINION LIPID PANEL.
(PRINCIPAL INVESTIGATOR, 2016)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN TRIAL OF WEEKLY LOW-DOSE METHOTREXATE (LDM) IN THE PREVENTION OF CARDIOVASCULAR EVENTS AMONG STABLE CORONARY ARTERY DISEASE PATIENTS WITH TYPE 2 DIABETES OR METABOLIC SYNDROME.
(PRINCIPAL INVESTIGATOR, 2016)

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE – THE EVOLVE-1 STUDY
(PRINCIPAL INVESTIGATOR, 2015)

USABILITY AND HBA1C METHOD COMPARISON STUDY USING LAY-PERSON MICRO-BLOOD SPECIMENS
(PRINCIPAL INVESTIGATOR, 2015)

PROCUREMENT OF MATCHED PAIRS OF VENIPUNCTURE AND CAPILLARY BLOOD SPECIMENS FOR CORRELATION STUDIES. (PRINCIPAL INVESTIGATOR, 2015)

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMG 334 IN MIGRAINE PREVENTION
(PRINCIPAL INVESTIGATOR, 2014)

A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMG 334 IN MIGRAINE PREVENTION
(PRINCIPAL INVESTIGATOR 2013)

A PHASE IIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY OF MK-1602 IN THE TREEATMENT OF ACUTE MIGRAINE
(PRINCIPAL INVESTIGATOR 2012)

CLINICAL EVALUATION OF THE WHOLE BLOOD AND SERUM PRECISION OF THE AFINION LIPID PANEL (ABROAD)
(PRINCIPAL INVESTIGATOR 2012)

CLINICAL EVALUATION OF THE ACCURACY OF THE AFINION LIPID PANEL TEST IN A POINT OF CARE SETTING (ACTION)
(PRINCIPAL INVESTIGATOR 2012)

A 52 WEEK EXTENSION TO: A PHASE IIB, RANDOMIZED, PLACEBO AND ACTIVE COMPARATOR (TOLTERODINE) CONTROLLED, 2 - PART CLINICAL STUDY OF THE EFFICACY AND SAFETY OF MK-4618 IN PATIENTS WITH OVERACTIVE BLADDER
(PRINCIPAL INVESTIGATOR 2012)

A PHASE IIB, RANDOMIZED, PLACEBO AND ACTIVE COMPARATOR (TOLTERODINE) CONTROLLED, 2 - PART CLINICAL STUDY OF THE EFFICACY AND SAFETY OF MK-4618 IN PATIENTS WITH OVERACTIVE BLADDER
(PRINCIPAL INVESTIGATOR 2011)

EVALUATION OF CAPSULE ENDOSCOPY WITH PILLCAM COLON 2 IN VISUALIZATION OF THE COLON
(2011)

THE ADD-CKD STUDY: AWARENESS, DETECTION, AND DRUG THERAPY IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE
(PRINCIPAL INVESTIGATOR 2011)

A 6-MONTH, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE INCIDENCE OF GASTRIC ULCERS FOLLOWING ADMINISTRATION OF EITHER PA32540 OR ENTERIC COATED ASPIRIN 325 MG IN SUBJECTS WHO ARE AT RISK FOR DEVELOPING ASPIRIN-ASSOCIATED ULCERS
(PRINCIPAL INVESTIGATOR 2010)

A WORLDWIDE, OPEN LABEL, CLINICAL TRIAL TO EXAMINE THE LONG TERM SAFETY AND TOLERABILITY OF RIZATRIPTAN IN PEDIATRIC MIGRAINEURS 12 TO 17 YEARS OF AGE FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA.
(PRINCIPAL INVESTIGATOR 2010)

A WORLDWIDE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF RIZATRIPAN FOR THE ACUTE TREATMENT OF MIGRAINE IN CHILDREN AND ADOLESCENTS.
(PRINCIPAL INVESTIGATOR 2010)

A PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF ZOSTAVAX IN SUBJECTS 50-59 YEARS OF AGE
(PRINCIPAL INVESTIGATOR 2010)

A CLINICAL OUTCOMES STUDY OF DARAPLADIB VERSUS PLACEBO IN SUBJECTS WITH CHRONIC CORONARY HEART DISEASE TO COMPARE THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE). THE STABILIZATION OF ATHEROSCLEROTIC PLAQUE BY INITIATION OF DARAPLADIB THERAPY TRIAL (STABILITY)
(PRINCIPAL INVESTIGATOR 2009)

A PHASE IIA, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-0974 FOR MIGRAINE PROPHYLAXIS IN PATIENTS WITH EPISODIC MIGRAINE.
(PRINCIPAL INVESTIGATOR 2009)

A MULTI-CENTER, LONG-TERM, OPEN-LABEL EXTENSION STUDY OF [S,S]-REBOETINE (PNU-165442G) ADMINISTERED ONCE DAILY IN PATIENTS WITH FIBROMYALGIAS
(PRINCIPAL INVESTIGATOR 2008)

A PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, IMMUNOGENICITY, SAFETY AND TOLERABILITY OF ZOSTAVAX IN SUBJECTS 50 - 59 YEARS OF AGE
(PRINCIPAL INVESTIGATOR 2008)

A 14-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY OF [S,S]-REBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY (QD) IN PATIENTS WITH FIBROMYALGIA
(PRINCIPAL INVESTIGATOR 2008)

A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP MULTIPLE ATTACKS STUDY TO COMPARE THE EFFICACY AND SAFETY OF ORAL MK-0974 WITH PLACEBO FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
(PRINCIPAL INVESTIGATOR 2008)

A MULTICENTER, DOUBLE-BLIND, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF ORAL MK-0974 WITH PLACEBO AND ZOLMITRIPTAN FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
(PRINCIPAL INVESTIGATOR 2007)

A MULTICENTER, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EXAMINE THE SAFETY, TOLERABILITY AND EFFICACY OF ORAL MK-0974 FOR THE LONG TERM TREATMENT OF ACUTE MIGRAINE WITH OR WITHOUT AURA
(PRINCIPAL INVESTIGATOR 2007)

A RANDOMIZED-WITHDRAWAL PHASE III STUDY EVALUATING THE SAFETY AND EFFICACY OF CG5503 EXTENDED-RELEASE (ER) IN SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (DPN)
(PRINCIPAL INVESTIGATOR, 2007)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3, THREE ARM STUDY OF THE SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
(PRINCIPAL INVESTIGATOR 2006)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 STUDY TO EVAUATE THE LONG-TERM SAFETY OF ALVIMOPAN 0.5 MG TWICE DAILY FOR 12 MONTHS FOR THE TREATMENT OF OPIOID-INDUCED BOWEL DYSFUNCTION IN ADULTS TAKING OPIOID THERAPY FOR PERSISTENT NON-CANCER PAIN.
(PRINCIPAL INVESTIGATOR, 2005)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY ALVIMOPAN 0.5MG ONCE DAILY AND 0.5MG TWICE DAILY FOR 12 WEEKS FOR THE TREATMENT OF OPIOID-INDUCED BOWEL DYSFUNCTION IN ADULTS TAKING OPIOID THERAPY FOR PERSISTENT NON-CANCER PAIN
(PRINCIPAL INVESTIGATOR, 2005)

RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF 3 ½ DAY COMBINATIONS OF 17B-ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL DELIVERY SYSTEMS FOR RELIEF OF MENOPAUSAL VASOMOTOR SYMPTOMS AND REDUCTION OF ENDOMETRIAL HYPERPLASIA
(PRINCIPAL INVESTIGATOR, 1997 - 2000)

A DOUBLE-BLIND, PARALLEL, PLACEBO CONTROLLED, MULTICENTER, POLYSOMOGRAPHIC STUDY OF THE EFFECTS OF L-759274 AND ZOLPIDEM IN PATIENTS WITH CHRONIC INSOMNIA
(SUBINVESTIGATOR, 1999 - 1999)

L-MARC HOME PAGE